Novo Nordisk A/S News - September 21, 2026

Novo Nordisk’s CagriSema Beats Eli Lilly in Weight Loss Trial

Novo Nordisk announced positive topline results for its next-generation experimental drug, CagriSema, during its Capital Markets Day. The late-stage REIMAGINE...

🔴 Novo Nordisk is trading 6% down; no confirmed September 21, 2026 announcement explains decline

Novo Nordisk is trading 6.23% down at DKK 264.00, with no confirmed September 21, 2026 company announcement directly explaining the decline. - Investors are...